As previously featured at the American College of Gastroenterology’s (ACG) 2023 Annual Scientific Meeting in Vancouver, British Columbia, the Social Determinants Acute Tool (S-DAT) is designed to treat alcoholic liver disease. It was associated with significant sensitivity indicating the ability to accurately identify patients. Increase or decrease in risk of alcohol relapse after liver transplantation.1
While the findings are exciting for the liver medical community, there is much more to be learned from this initial study as alcoholic liver disease is rapidly increasing in the United States.
In the second segment of the interview, HCP Live At ACG 2023, University of Tennessee Health Science Center researcher Jiten P. Kotadia, MD, discussed significant results from his team’s research on the S-DAT scoring system. This tool could help clinicians identify patients with alcoholic liver disease who: It lowers the risk of alcohol relapse and helps prioritize early transplantation.
Kotadia said this could, in theory, be beneficial in facilitating efficient and timely intervention, especially for patients suffering from liver disease or who lack adequate care resources other than transplantation. said.
“And at the same time, for people who have identified risk factors[with S-DAT]we can intervene before transplant to set them on the right healthy path,” Cosadia said. “After transplantation, we can monitor this patient closely depending on their risk score.”
Kotadia also sees benefits in helping his colleagues devote time and resources to treating alcoholic liver disease, an emerging public health crisis that clinicians have previously talked about. HCP Live There is a lack of sufficient staffing and treatment options to contain it.2
“It could also help determine how many times these patients should see a psychologist or psychiatrist, or whether they should be monitored more closely, compared to other patients,” he said.
Although this trial is limited by its single-center setting and retrospective analysis method, Dr. Kotadia said it represents the introduction of a multifactorial tool that considers all individual components of alcohol relapse risk in patients with alcoholic liver disease. , said it would be an interesting material for excellent research. It also provides opportunities for colleagues to implement it in their own practice.
“And there are so many factors that need to be considered to ultimately provide the best medical outcomes and provide a comprehensive protocol of care that improves long-term survival and quality of life. is the goal of any intervention, whether it’s a transplant or a drug: to improve quality of life and improve patient survival.
- Kothadia JP, Dash A, Rong J, Liu TY et al Predicting low risk of alcohol relapse within 1 year after liver transplantation for alcoholic liver disease: S-DAT score. Paper presentation: ACG 2023 Annual Academic Conference. Vancouver, British Columbia, Canada. From October 20th to 25th, 2023.
- Kunzman K. Relentless: The simultaneous epidemics of alcohol abuse and liver disease in the United States. HCP Live. Published October 3, 2023. https://www.hcplive.com/view/concurrent-alcohol-abuse-liver-disease-epidemics-us